Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Proqr Therapeutics (PRQR)

Proqr Therapeutics (PRQR)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
1.1200 -0.0100 (-0.88%) 04/11/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 1.1500 +0.0300 (+2.68%) 16:30 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.0900
Day High
1.1900
Open 1.1200
Previous Close 1.1300 1.1300
Volume 762,600 762,600
Avg Vol 729,650 729,650
Stochastic %K 13.11% 13.11%
Weighted Alpha -80.25 -80.25
5-Day Change -0.0600 (-5.08%) -0.0600 (-5.08%)
52-Week Range 1.0700 - 4.6200 1.0700 - 4.6200
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 117,839
  • Shares Outstanding, K 105,213
  • Annual Sales, $ 20,460 K
  • Annual Income, $ -30,040 K
  • EBIT $ -33 M
  • EBITDA $ -30 M
  • 60-Month Beta 0.25
  • Price/Sales 5.81
  • Price/Cash Flow N/A
  • Price/Book 1.24

Options Overview Details

View History
  • Implied Volatility 496.36% ( +219.07%)
  • Historical Volatility 57.30%
  • IV Percentile 92%
  • IV Rank 58.56%
  • IV High 828.07% on 02/07/25
  • IV Low 27.68% on 05/22/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 20
  • Volume Avg (30-Day) 30
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 1,147
  • Open Int (30-Day) 1,919

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.09
  • Number of Estimates 3
  • High Estimate -0.03
  • Low Estimate -0.14
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0700 +4.67%
on 04/09/25
Period Open: 1.8500
1.8700 -40.11%
on 03/12/25
-0.7300 (-39.46%)
since 03/11/25
3-Month
1.0700 +4.67%
on 04/09/25
Period Open: 2.4200
2.6700 -58.05%
on 02/20/25
-1.3000 (-53.72%)
since 01/10/25
52-Week
1.0700 +4.67%
on 04/09/25
Period Open: 2.3000
4.6200 -75.76%
on 10/17/24
-1.1800 (-51.30%)
since 04/11/24

Most Recent Stories

More News
ProQR Therapeutics Appoints Dr. Peter Beal as Chief ADAR Scientist to Advance RNA Editing Platform

ProQR Therapeutics appoints Dr. Peter Beal as Chief ADAR Scientist to enhance RNA editing technology development.Quiver AI SummaryProQR Therapeutics has appointed Dr. Peter Beal, a prominent expert in...

PRQR : 1.1200 (-0.88%)
ProQR: Q3 Earnings Snapshot

ProQR: Q3 Earnings Snapshot

PRQR : 1.1200 (-0.88%)
Best Momentum Stocks to Buy for October 2nd

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, October 2:BRF S.A. BRFS: This meat processing company has a Zacks Rank #1 and witnessed the Zacks...

BRFS : 3.49 (+2.35%)
SNAX : 0.4550 (unch)
PRQR : 1.1200 (-0.88%)
ProQR: Q2 Earnings Snapshot

ProQR: Q2 Earnings Snapshot

PRQR : 1.1200 (-0.88%)
ProQR: Q3 Earnings Snapshot

ProQR: Q3 Earnings Snapshot

PRQR : 1.1200 (-0.88%)
ProQR: Q2 Earnings Snapshot

ProQR: Q2 Earnings Snapshot

PRQR : 1.1200 (-0.88%)
ProQR: Q1 Earnings Snapshot

ProQR: Q1 Earnings Snapshot

PRQR : 1.1200 (-0.88%)
Why Shares of ProQR Therapeutics Dropped on Wednesday

The clinical-stage biotech released fourth-quarter and full-year earnings.

LLY : 732.41 (+1.60%)
PRQR : 1.1200 (-0.88%)
Lilly and ProQR to Expand RNA Editing Collaboration

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and ProQR Therapeutics N.V. (Nasdaq: PRQR), today announced the expansion of their licensing and...

LLY : 732.41 (+1.60%)
PRQR : 1.1200 (-0.88%)
ProQR: Q3 Earnings Snapshot

ProQR: Q3 Earnings Snapshot

PRQR : 1.1200 (-0.88%)

Business Summary

ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the...

See More

Key Turning Points

3rd Resistance Point 1.2767
2nd Resistance Point 1.2333
1st Resistance Point 1.1767
Last Price 1.1200
1st Support Level 1.0767
2nd Support Level 1.0333
3rd Support Level 0.9767

See More

52-Week High 4.6200
Fibonacci 61.8% 3.2639
Fibonacci 50% 2.8450
Fibonacci 38.2% 2.4261
Last Price 1.1200
52-Week Low 1.0700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar